Abstract
Objective
Prostate-specific membrane antigen (PSMA)-PET/CT imaging has gained increasing clinical importance for the detection and staging of high-risk primary prostate cancer (PCa). However, it is unclear whether the routine practice of prostate biopsy obscures the image finding of PSMA-PET/CT. This study aimed to compare the tumor positivity rate of PSMA-PET/CT performed pre- (PSMA-PET/CTpre) and post-biopsy (PSMA-PET/CTpost) in high-risk PCa patients.
Patients and methods
We matched 58 PSMA-PET/CTpost with 58 PSMA-PET/CTpre studies for primary detection of high-risk PCa according to clinical characteristics. Three subgroups of PSMA-PET/CTpost were defined by the intervals after biopsy (≤ 1 week, 1 ~ 2 weeks, and 2 ~ 5 weeks). Tumor positivity rates were determined, and SUVmax of primary tumors were compared separately for the two main groups and the related subgroups. Malignant prostate tissues from 20 of these patients were examined by immunohistochemical analysis of PSMA. In addition, the values of PSMA-PET/CTpre and PSMA-PET/CTpost in assessing seminal vesicle invasion (SVI) were evaluated in patients who underwent radical prostatectomy.
Results
All the primary tumors were positive on PSMA-PET/CTpost and PSMA-PET/CTpre imaging, resulting in a patient-based positivity rates of 100% (58/58) in both groups. All examined IHC results (20/20) confirmed the high-level expression of PSMA. SUVmax of primary tumors did not differ between the two main groups (16.1, IQR 9.8–26.6 vs. 16.5, IQR 11.0–26.7, p > 0.05). Subgroup analysis of PSMA-PET/CTpost (≤ 1 week, 1 ~ 2 weeks, and 2 ~ 5 weeks) also showed no significant difference in tumor SUVmax (15.8, IQR 9.5–22.2; 17.8, IQR 9.8–29.2; and 15.4, IQR 10.1–30.3. p > 0.05). PSMA-PET/CTpost and PSMA-PET/CTpre exhibited similar value in SVI detection as well.
Conclusions
The tumor positivity rate was consistently high for PSMA-PET/CT pre- and post-biopsy. A prior biopsy does not seem to affect the tumor positivity rate of PSMA-PET/CT in high-risk PCa.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Prostate cancer (PCa) is currently the most common neoplasm in males and the second leading cause of cancer-related deaths for males in western countries [1]. Standard procedure for PCa diagnosis includes detection of elevated prostate-specific antigen (PSA) level and digital rectal examination (DRE) in patients [2].
Imaging techniques opens up a new horizontal for the diagnosis and management of males linked with risk of prostate cancer. Multiparametric magnetic resonance imaging (mpMRI), for example, proves to be a valuable tool for risk stratification, biopsy guidance, and local staging of clinically significant PCa [3, 4]. The procedure of invasive prostate biopsy, however, may cause biopsy-related artifacts including hemorrhage and edema in the imaging results, and subsequently lead to over- or under-estimation of tumor burden. As a result, prostate MRI is usually performed prior to a biopsy and the use of MRI in PCa management within a short time after biopsy should be cautioned [5, 6], especially in those with previous negative or inconclusive biopsy reports.
Prostate-specific membrane antigen (PSMA) is a transmembrane protein with a 100- to 1000-times higher expression in primary and metastatic prostate tumors than in normal tissues [7, 8]. PSMA-targeted positron emission tomography (PET) is increasingly used to assess the recurrence of PCa as well as to localize primary disease and metastases [9,10,11,12,13,14,15,16,17]. The recent prospective PRIMARY trial [18] showed that the combination of PSMA-PET and mpMRI was superior to mpMRI alone in the diagnosis of clinically significant PCa. While PSMA-PET gains popularity as the primary diagnostic modality for PCa, it is also brought to attention that a pre-imaging biopsy may compromise the performance of PSMA-PET/CT or PSMA-PET/MR, in a similar way to that of MRI. On the other hand, the imaging results of PSMA-PET/CT are reconstructed from the distribution of PSMA molecules rather than anatomical features, and therefore, may be unaffected by the biopsy-related artifacts. Up to date, it is unclear if a biopsy affects the tumor positivity rate of the ensuing PSMA-PET/CT for primary PCa, or whether it is necessary to implicate a waiting-period between the biopsy and the following PSMA-PET/CT.
Therefore, we herein present this retrospective, matched-pair analysis to assess the tumor positivity rate of pre- and post-biopsy 68Ga-PSMA-PET/CT in patients with high-risk PCa.
Patients and methods
Patients
Fifty-eight patients (mean age 68.1 ± 7.8 years; range 50–81 years) with newly diagnosed high-risk PCa who underwent post-biopsy 68Ga-PSMA-617 PET/CT (PSMA-PET/CTpost) at our institution from April 2018 to December 2020 were consecutively enrolled and retrospectively analyzed. Based on the European Association Urology guidelines, high-risk patients were defined as those with the presence of one or more of the following criteria: PSA concentration > 20 ng/mL, ISUP grade group ≥ 4, or clinical stage ≥ T2c [19]. Of these, 48 had undergone a transrectal ultrasonography (TRUS)-guided transrectal 12-core prostate biopsy, 1 had trans-perineal mpMRI targeted biopsy (8 + 1-core) and 9 outpatient received biopsy in other institutions with unknown approaches and number of needle cores. All patients were examined by 68Ga-PSMA-PET/CT within 5 weeks after prostate biopsy (PSMA-PET/CTpost) and were subcategorized into three subgroups based on the interval between biopsy and PSMA-PET/CT: ≤ 1 week, 1 ~ 2 weeks, and 2 ~ 5 weeks. Patients with a history of electron-prostatectomy or being treated with anti-cancer therapy prior to PSMA-PET/CT scan were excluded. PSA values tested within 5 weeks before PSMA-PET/CT were identified. Available post-biopsy MRI data of these patients for pretreatment local staging were also reviewed to determine the presence or absence of hemorrhage. Of the 58 PSMA-PET/CTpost patients, 28 underwent radical prostatectomy (RP) within 1 month after the PSMA-PET/CT scan.
Fifty-eight corresponding patients (mean age 69.7 ± 8.7 years; range 46–85 years) with pathology-confirmed PCa who had undergone 68Ga-PSMA-PET/CT before prostate biopsy (PSMA-PET/CTpre) during the same time period were consecutively identified in the institution’s database on the basis of the following clinical parameters: ISUP grade group (2–3 vs. 4–5), pre-scan PSA values (4–20 ng/mL, > 20 ≤ 100 ng/mL vs. > 100 ng/mL and clinical Tumor stage (cT) (cT2c, cT3 vs. cT4). Characteristics of the matched-pair cohorts are summarized in Table 1. For PSMA-PET/CTpre patients, there were longer time intervals between biopsy, radical prostatectomy, and the post-biopsy PSMA-PET, which resulted in patient dropouts from the study. Of the 58 PSMA-PET/CTpre patients, 14 underwent RP within 1 month after the examination.
This study was approved by the Ethics Committee of the Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (No. TJ-IRB20190422). All reported investigations were conducted in accordance with the Helsinki Declaration and national regulations. Patient data were de-identified and processed per institutional ethics guidelines.
Imaging procedure
68Ga-PSMA-617 was administered as an intravenous bolus at a dose of 89–200 MBq (mean 114.6 ± 30.9 MBq) and PET acquisition was started at a mean ± SD time of 60 ± 11 min after tracer injection on a dedicated PET/CT hybrid tomography (GE Discovery 690, General Electronic Healthcare, USA). Image acquisition was started with a non-enhanced helical CT scan using automatic mA-modulation and 120 kV. CT scans were reconstructed to a slice thickness of 3.75 mm. PET scans were acquired in 3D mode with an acquisition time of 120 ~ 180 s per bed position from the mid-thighs to the skull base. PET images were reconstructed with the built-in GE VUE point method.
PET image analysis and quantification
All PSMA-PET/CTpost and PSMA-PET/CTpre imaging were evaluated by two board-certified nuclear medicine physicians with specific training in 68Ga-PSMA-PET/CT in consensus. Readers were blinded to patients’ history and histopathological results. The scan was considered positive when intraprostatic tracer uptake higher than liver was noticed as reported in the PROstate cancer Molecular Imaging Standardized Evaluation (PROMISE) study [20]. Tumor uptake patterns were classified as unilateral focal, bilateral multifocal, and increased diffuse uptake. Maximum standardized uptake value (SUVmax) of the suspected prostate tumors with the highest PSMA-ligand uptake was noted. Seminal vesicle invasion was defined by the presence of focal or diffuse PSMA-ligand accumulation above the background by visual analysis. PROMISE criteria were adopted for interpretation of PSMA uptake in lymph node and bone metastases [20]. Tumor positivity rates were determined separately for PSMA-PET/CTpost and PSMA-PET/CTpre group. SUVmax of primary tumors were compared in (1) the PSMA-PET/CTpost and PSMA-PET/CTpre groups, (2) three subgroups of PSMA-PET/CTpost patients with different intervals after biopsy (≤ 1 week, 1 ~ 2 weeks and 2 ~ 5 weeks), (3) patients with organ-confined tumor and those with locally advanced PCa (pT2 vs. ≥ pT3) and (4) patients with and without PSMA-avid lymph nodes (N) and bone metastases (BM): (N+ BM+, N− BM+, N+ BM− and N− BM−). The correlations of tumor SUVmax with the tPSA level, ISUP grade, and pT were also analyzed.
Pathological and immunohistochemical (IHC) analyses
A total of 42 (28 from PSMA-PET/CTpost group and 14 from PSMA-PET/CTpre group) patients underwent radical prostatectomy with resection of the seminal vesicles. PSMA was stained with an anti-PSMA rabbit monoclonal antibody (EPR6253, ab133579, Abcam, 1:500 dilution) on a Leica Bond-Max auto-stainer. The intensity of staining (weak, moderate or intense) and the percentage of positively stained cells (focal, regional, or diffuse) were graded as reported in a previous study [21]. Cases categorized as intense diffuse, intense regional, or moderate diffuse were considered as overexpressing PSMA protein.
Statistical analysis
Statistical analyses were performed using SPSS version 26.0 software (IBM Corp., Armonk, New York). Quantitative data are expressed as mean values ± standard deviations (SD) or medium ± interquartile range (IQR). Tumor positivity rates were determined separately for the two groups. The sensitivity, specificity and accuracy of PSMA-PET/CT for evaluating SVI were calculated using histopathology results of RP as the reference standard. For comparisons of the tumor SUVmax between groups and in subgroups, p values were calculated by the Mann–Whitney U test. The correlations of tumor SUVmax with the tPSA level, ISUP grade, and pT were analyzed using Spearman’s correlation. p values < 0.05 were considered statistically significant.
Results
Tumor positivity rate of 68Ga-PSMA-PET/CTpost and 68Ga-PSMA-PET/CTpre
Primary tumor and PSMA protein expression by IHC
All the primary tumors were positive on PSMA-PET/CTpost and PSMA-PET/CTpre (both 100%, 58/58) imaging. Twenty prostatectomy specimens from these primary tumors were available for immunohistochemistry, all of which showed strong expression of PSMA.
The SUVmax values of primary tumors did not differ between the PSMA-PET/CTpost and PSMA-PET/CTpre groups (16.1, IQR 9.8–26.6 vs. 16.5, IQR 11.0–26.7, p > 0.05). Neither did the subgroup analysis of PSMA-PET/CTpost (≤ 1 week, 1 ~ 2 weeks, and 2 ~ 5 weeks) show any significant difference in the SUVmax of tumor (15.8, IQR 9.5–22.2; 17.8, IQR 9.8–29.2; and 15.4, IQR 10.1–30.3. p > 0.05) (Table 2). In terms of the pattern of tumor uptake, PSMA-PET/CT revealed diffuse infiltration, bilateral focal and unilateral focal prostate tumor in 64% (37/58), 17% (10/58) and 19% (11/58) of PSMA-PET/CTpost patients, respectively, and in 64% (37/58), 15% (9/58) and 21% (12/58) of PSMA-PET/CTpre patients in comparison (Supplemental Fig. 1).
Moreover, the SUVmax of primary tumor was significantly higher in patients with locally advanced PCa (≥ pT3; 16.3, IQR 11.4–30.0) as compared to that in organ-confined PCa (pT2; 9.5, IQR 7.9–16.8) (p = 0.041). Difference in the uptake by primary tumor was also recorded among individuals with and without metastases: N+ BM+ (42.3%, 49/116, median 16.6), N− BM+ (11.2%, 13/116, 11.5), N+ BM− (17.2%, 20/116, 24.4) and N− BM− (29.3%, 34/116, 15.9), respectively, p = 0.043) (Table 2 and Supplemental Fig. 2).
Post-biopsy MR imaging for preoperative local staging was available for review in eight of the PSMA-PET/CTpost patients, and hemorrhages was observed in seven of them. In contrast to the intense PSMA-ligand uptake in prostate tumors, the uptake in hemorrhage regions was minimal. Representative images of 68Ga-PSMA-617 scans are shown in Figs. 1–5: primary tumor at 5 days (Fig. 1) and 1 week (Fig. 2) after prostate biopsy, bilateral focal lesions in prostate at 3 weeks after biopsy (Fig. 3), single focal lesion in prostate at 1 month after biopsy (Fig. 4), and increased tumor uptake prior to biopsy (Fig. 5).
Seminal vesicle invasion (SVI)
Using histopathological results of resected samples as the reference standard, the sensitivity, specificity and accuracy of imaged-based SVI detection were calculated as the following: PSMA-PET/CTpost: 84.6% (11/13), 100.0% (15/15), and 92.9% (26/28); PSMA-PET/CTpre: 87.5% (7/8), 100.0% (6/6), and 92.9% (13/14) (Table 3). Therefore, pre- and post-biopsy PSMA-PET/CT scans exhibited similar diagnostic performance in SVI detection.
Correlation of tumor SUVmax in PSMA-PET/CT and other parameters
A slightly positive correlation was observed between tumor SUVmax and the pT stage (r = 0.316, p < 0.05) in patients who underwent RP. There was a similar positive correlation between the tumor SUVmax and tPSA value (r = 0.358, p < 0.01) in PSMA-PET/CTpre patients. However, no significant correlation between tumor SUVmax and pre-scan tPSA value was found in the PSMA-PET/CTpost patients (r = − 0.012, p > 0.05) (Fig. 6). Neither was a correlation established between ISUP grade and the tumor SUVmax (r = 0.085, p > 0.05).
Discussion
With the current shift towards an early PSMA-PET/CT scan for the primary diagnosis and staging of PCa, it is imperative to understand the potential impact of biopsy on the imaging quality and diagnostic power of the ensuing PET. Previous studies have demonstrated that PSMA-PET/CT could yield remarkable results for the pre-surgery identification of primary high-risk PCa and metastases [22,23,24]. For example, Fendler et al. [25] reported that 68Ga-PSMA-PET/CT performed minimally 1-week post-biopsy could present satisfactory diagnostic accuracy for the detection of primary lesions. Nevertheless, the time interval between biopsy and the following PET/CT has yet to be specified in most of the studies. Therefore, we postulated that an evaluation on the impact of biopsy timing upon the tumor positivity rate of PSMA-PET/CT would help fill such a knowledge gap.
Our results demonstrate the pre- and post-biopsy PSMA-PET/CT both detected 100% of primary high-risk PCa lesions, showing no significant difference in SUV max of the primary tumors. Subgroup analysis of patients undergoing PSMA-PET/CTpost revealed that the time interval between biopsy and ensuing PET scan did not have a significant impact on the SUVmax values of tumors. Neither did this time interval have any effects on the performance of PET/CT in locating tumor nodules. Taken together, we have shown that biopsy is unlikely to compromise the diagnostic power of ensuing PSMA-PET/CT for primary or metastatic lesions, and any delay of the post-biopsy PET scan is unnecessary. Our results provide valuable guidelines for clinicians, as an example, in scheduling a timely PSMA-PET scan for a high-risk patient that has a negative or inconclusive biopsy report.
Hemorrhage is the most frequent complication in prostate biopsy, and has been detected in MRI scans on 72.2%, 57.1%, and 52% patients at < 4, 4 ~ 6, and > 6 weeks after the biopsy, respectively [26]. While there have been no reports on the impact of biopsy-induced hemorrhage on the detectability of PSMA-PET in PCa, our study confirmed that hemorrhage or blood products did not take up radiotracers in PSMA-PET. In comparison, there was an intense uptake of radiotracers in pathologically verified prostate tumors. Therefore, we concluded that in spite of biopsy-induced hemorrhage, PSMA-PET/CT was capable of detecting primary tumor lesions in patients with high-risk PCa, regardless of the time interval between biopsy and PET.
PSAM-PET/CT’s ability to withstand the interference by a prior biopsy can be attributed to the following factors. First, the high PSMA expression in PCa enables a specific imaging of PSMA molecules in prostate tumors [7, 8]. Preclinical studies have shown that prostate tumors exhibited highly homogenous and intense expression of PSMA [27, 28]. The IHC results of patients in our study also validated that PSMA was homogenously overexpressed throughout the prostate tumors, which constituted the molecular pre-requisite for increased tumor uptake of PSMA ligands. Second, the blood products of hemorrhage did not take up PSMA ligands. Third, the extent of post-biopsy hemorrhage was less severe in prostate tumor than in peritumor normal tissues, which became even less significant as the tumor size increased and the percentage of normal tissues dropped [29]. Notably, 64% of patients with advanced and large tumors in both study groups were presented with diffuse intense tumor uptake on PSMA-PET imaging, enabling PSAM-PET/CT ability to offset the interference. Fourth, the biopsy-related hemorrhage in tumor foci may have resolved spontaneously more rapidly than in normal prostatic tissue [30]. Lastly, PSMA expression in inflammatory lesions was reported to be extremely rare [7].
In our results, the tumor positivity rates and SVI detection value for 68Ga-PSMA-PET/CTpost and 68Ga-PSMA-PET/CTpre are slightly higher than those reported in the previous studies [23, 29, 31,32,33], probably because PSA screening for early detection of PCa has not been widely adopted and therefore more patients already had advanced-stage tumors at the time of PET scans [34].
In line with previous studies, the tumor SUVmax was found to be higher in locally advanced PCa (≥ pT3) than organ-confined tumor (pT2) (p < 0.05) in patients who underwent RP (Table 2). However, the radiotracer uptake of primary lesions in patients with metastatic PCa was not consistently higher than that in patients without metastasis. Mannweiler et al. reported that metastatic PCa exhibited significant intra- and inter- tumor heterogeneity [35]. Silver et al. showed that metastatic lesions tended to have higher PSMA expression than primary lesions, whereas nodule metastases had higher PSMA expression than bone metastases [7]. Therefore, the variability of the intraprostatic uptake of PSMA-ligand may be caused by the inherent heterogeneity of metastatic PCa. The intensity of intraprostatic tracer uptake, however, did not have any impact on patient management in these metastatic cases.
Moreover, a slightly positive correlation was found between tumor uptake of PSMA and the pT stage in patients who underwent RP as well as the tumor SUVmax and tPSA value in PSMA-PET/CTpre patients. These findings were consistent with those of previous studies [22, 24, 36]. However, no significant correlation between the tumor SUVmax and pre-scan tPSA value was found in the PSMA-PET/CTpost patients. This could be attributed to the spurious transient elevation of serum PSA associated with mechanical manipulation of the prostate by biopsy or catheterization in the post-biopsy cohort [37]. In addition, we did not observe a significant correlation between the tumor SUVmax and the ISUP grade, which can be explained in part by the small number of patients with ISUP grade 2 and 3 and the potential disagreement of ISUP grade between biopsy and prostatectomy specimens might be the underlying reasons [38].
Our study has some limitations. First, this is a retrospective matched-pair comparison in high-risk PCa patients conducted in a single institute. Second, the limited sample size and distribution of cancer risk population may also cause a potential bias. Third, the needle biopsy of the prostate was performed by physicians from different institutions, and their technique or the number of needle cores varied. In addition, a direct comparison between PSMA-PET/CTpost with post-biopsy MRI imaging was not available for the whole cohort, as MRI is not mandatory in the post-biopsy setting in our institution. Meanwhile, whole-mount step-section of pathologic specimens from prostatectomy was not performed as a routine analysis. Thus, PSMA-PET/CT for PCa diagnosis was not evaluated using lesion-based analysis. Therefore, further investigations using a head-to-head comparison of PSMA-PET performed before and after prostate biopsy in a greater spectrum of cancer risk population are warranted.
Conclusion
The tumor positivity rate was consistently high for PSMA-PET/CT pre- and post-biopsy. A prior biopsy does not seem to affect the tumor positivity rate of PSMA-PET/CT in high-risk PCa.
References
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA. 2020;70(1):7–30.
Hubner N, Shariat S, Remzi M. Prostate biopsy: guidelines and evidence. Curr Opin Urol. 2018;28(4):354–9.
Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815–22.
Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol. 2011;59(4):477–94.
Chatterjee A, Thomas S, Oto A. Prostate MR: pitfalls and benign lesions. Abdom Radiol. 2020;45(7):2154–64.
Siegel C. Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. J Urol. 2005;174(2):569.
Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81–5.
Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate. 2011;71(3):281–8.
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208–16.
Aragon-Ching JB. The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer. Asian J Androl. 2021;23(1):1–2.
Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(4):486–95.
Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197–209.
Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. (68)Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imagin. 2017;44(6):1014–24.
Schmuck S, Mamach M, Wilke F, von Klot CA, Henkenberens C, Thackeray JT, et al. Multiple time-point 68Ga-PSMA I&T PET/CT for characterization of primary prostate cancer: value of early dynamic and delayed imaging. Clin Nucl Med. 2017;42(6):e286–93.
Prive BM, Israel B, Schilham MGM, Muselaers CHJ, Zamecnik P, Mulders PFA, et al. Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. Prostate Cancer Prostatic Dis. 2021;24(2):423–30.
Koseoglu E, Kordan Y, Kilic M, Sal O, Seymen H, Kiremit MC, et al. Diagnostic ability of Ga-68 PSMA PET to detect dominant and non-dominant tumors, upgrading and adverse pathology in patients with PIRADS 4–5 index lesions undergoing radical prostatectomy. Prostate Cancer Prostatic Dis. 2021;24(1):202–9.
Scobioala S, Kittel C, Wolters H, Huss S, Elsayad K, Seifert R, et al. Diagnostic efficiency of hybrid imaging using PSMA ligands, PET/CT, PET/MRI and MRI in identifying malignant prostate lesions. Ann Nucl Med. 2021;35(5):628–38.
Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. Eur Urol. 2021;80(6):682–9.
Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243–62.
Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-Ligand PET/CT. J Nucl Med. 2018;59(3):469–78.
Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9(17):6357–62.
Cytawa W, Seitz AK, Kircher S, Fukushima K, Tran-Gia J, Schirbel A, et al. (68)Ga-PSMA I&T PET/CT for primary staging of prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47(1):168–77.
von Klot CJ, Merseburger AS, Boker A, Schmuck S, Ross TL, Bengel FM, et al. (68)Ga-PSMA PET/CT imaging predicting intraprostatic tumor extent, extracapsular extension and seminal vesicle invasion prior to radical prostatectomy in patients with prostate cancer. Nucl Med Mol Imaging. 2017;51(4):314–22.
Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, et al. (68)Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging. 2017;44(6):941–9.
Fendler WP, Schmidt DF, Wenter V, Thierfelder KM, Zach C, Stief C, et al. 68Ga-PSMA PET/CT detects the location and extent of primary prostate cancer. J Nucl Med. 2016;57(11):1720–5.
Sharif-Afshar AR, Feng T, Koopman S, Nguyen C, Li Q, Shkolyar E, et al. Impact of post prostate biopsy hemorrhage on multiparametric magnetic resonance imaging. Can J Urol. 2015;22(2):7698–702.
Tsourlakis MC, Klein F, Kluth M, Quaas A, Graefen M, Haese A, et al. PSMA expression is highly homogenous in primary prostate cancer. Appl Immunohistochem Mol Morphol. 2015;23(6):449–55.
Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM Jr, Wang CY, et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg. 2006;30(4):628–36.
Tamada T, Sone T, Jo Y, Yamamoto A, Yamashita T, Egashira N, et al. Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis. Radiology. 2008;248(2):531–9.
Zakian KL, Shukla-Dave A, Ackerstaff E, Hricak H, Koutcher JA. 1H magnetic resonance spectroscopy of prostate cancer: biomarkers for tumor characterization. Cancer Biomark. 2008;4(4–5):263–76.
Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, et al. Risk of metastatic disease on (68) gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU Int. 2019;124(3):401–7.
Donato P, Morton A, Yaxley J, Ranasinghe S, Teloken PE, Kyle S, et al. (68)Ga-PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: is (68)Ga-PSMA PET/CT guided biopsy the future? Eur J Nucl Med Mol Imaging. 2020;47(8):1843–51.
Muehlematter UJ, Burger IA, Becker AS, Schawkat K, Hotker AM, Reiner CS, et al. Diagnostic accuracy of multiparametric MRI versus (68)Ga-PSMA-11 PET/MRI for extracapsular extension and seminal vesicle invasion in patients with prostate cancer. Radiology. 2019;293(2):350–8.
Peyromaure EM, Mao K, Sun Y, Xia S, Jiang N, Zhang S, et al. A comparative study of prostate cancer detection and management in China and in France. Can J Urol. 2009;16(1):4472–7.
Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009;15(2):167–72.
Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, et al. Head-to-head comparison of (68)Ga-PSMA-11 with (18)F-PSMA-1007 PET/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. J Nucl Med. 2020;61(4):527–32.
Vihko P, Lukkarinen O, Kontturi M, Vihko R. The effect of manipulation of the prostate gland on serum prostate-specific acid phosphatase measured by radioimmunoassay. Invest Urol. 1981;18(5):334–6.
Tomioka S, Nakatsu H, Suzuki N, Murakami S, Matsuzaki O, Shimazaki J. Comparison of Gleason grade and score between preoperative biopsy and prostatectomy specimens in prostate cancer. Int J Urol. 2006;13(5):555–9.
Funding
This work is supported by grants from the National Natural Science Foundation of China (No. 81873903, 91959119) and Natural Science Foundation of Hubei Province (No. 2020CFB586).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Ethical approval
The study is approved from the Institutional Review Board (No. TJ-IRB20190422).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
12149_2022_1732_MOESM2_ESM.tif
Supplementary file 2 (TIF 2025 KB) Differences in primary tumor uptake were recorded between surgery patients with different pT stage (A) as well as in patients with and without metastatic disease (B, N+ BM+, N-BM+, N+ BM-and N-BM-).
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Zou, S., Song, S., Zhou, J. et al. Time point-independent tumor positivity of 68Ga-PSMA-PET/CT pre- and post-biopsy in high-risk prostate cancer. Ann Nucl Med 36, 523–532 (2022). https://doi.org/10.1007/s12149-022-01732-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-022-01732-w